**Treatment of Tumor Cells with Mirvetuximab Soravtansine, a FRα-Targeting Antibody-Drug Conjugate (ADC), Activates Monocytes Through Fc-FcγR Interaction and Immunogenic Cell Death**

Anna Skaletskaya, Jose Ponte, Thomas Chittenden, Yulius Setiady

**INTRODUCTION**
- Mirvetuximab soravtansine (IMGN853) is an ADC comprising the humanized FRα-binding M9346A antibody linked to the tubulin-disrupting maytansinoid, DM4.
- IMGN853 binds to FRα on cancer cells and is internalized; DM4 is released through enzymatic degradation of the antibody and linker cleavage, resulting in disruption of cell division and cell death.
- IMGN853 showed encouraging single-agent activity and was generally well-tolerated in FRα-positive ovarian cancer patients in a Phase 1 study (NCT01609556).
- IMGN853 is entering FORWARD I, a Phase 3 monotherapy study, and is also being evaluated in combination with other agents, including the checkpoint inhibitor pembrolizumab, in a Phase 1b/2 study, FORWARD II (NCT02606305).
- This study explored potential mechanism(s) whereby IMGN853 can show enhanced activity in combination with a checkpoint inhibitor.

**MONOocyte ACTIVATION DEPENDS ON mAb’s Fc AND DM4**

Monocytes were isolated from peripheral blood of normal donors by negative selection and incubated with KB cells at a ratio of 3:1 in the presence of IMGN853 (10 nM) or M9346A (M) Ab (10 nM) or free maytansinoid (DM4) (1 nM) for 48 hours and stained for CD14 and CD86.

**IMGN853 TREATMENT OF KB CELLS ACTIVATES PERIPHERAL BLOOD MONOCYTES**

Peripheral blood mononuclear cells (PBMC) from normal donors were incubated with FRα-positive KB cells at 30:1 ratio in the presence or absence of test articles for 48 hours, stained for various phenotypic and activation markers, and analyzed by flow cytometry.

**IMGN853 TREATMENT OF KB CELLS DIRECTLY ACTIVATES MONOCYTES**

Monocytes were isolated from peripheral blood of normal donors by negative selection and incubated with KB cells at a ratio of 3:1 in the presence of IMGN853 (10 nM) for 48 hours, stained for CD14 and CD86, and analyzed by flow cytometry.

**IMGN853 INDUCES IMMUNOGENIC CELL DEATH OF KB CELLS**

KB cells were treated with 10 nM IMGN853 for 48 hours and immunogenic cell death markers were measured by flow cytometry (calreticulin) or ELISA (ATP and HMGB1). CRT (calreticulin), ATP, and HMGB1 (high mobility group box 1) engage CD91, P2RX7 receptors, and TLR4, respectively, and induce dendritic cells to engulf dying cells, IL-1β production and cross-presentation of tumor antigens.

**CONCLUSIONS**
- Treatment of FRα-expressing KB cells with IMGN853 induces activation of co-cultured monocytes through Fc-FcγR interaction and upregulation of immunogenic cell death markers.
- The activation of monocytes in the presence of tumor neoantigen would trigger T cell responses that would be further enhanced by an immune checkpoint inhibitor.